Ladenburg Thalmann Downgrades Eyenovia(EYEN.US) to Hold Rating
Eyenovia Cut to Neutral From Buy by HC Wainwright & Co.
William Blair Downgrades Eyenovia(EYEN.US) to Hold Rating
Eyenovia Analyst Ratings
Brookline Capital Downgrades Eyenovia(EYEN.US) to Hold Rating
Ladenburg Thalmann Maintains Eyenovia(EYEN.US) With Buy Rating, Cuts Target Price to $4.5
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia's Promising Growth Prospects: Buy Rating Affirmed by Analyst
Eyenovia Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia's Strategic Collaborations and Innovative Optejet System Underpin Buy Rating
H.C. Wainwright Maintains Eyenovia(EYEN.US) With Buy Rating, Maintains Target Price $12
Eyenovia Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
Eyenovia Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Eyenovia, Maintains $12 Price Target
Eyenovia Analyst Ratings
Eyenovia's Strategic Commercial Synergy and Growth Potential Reinforce Buy Rating
Eyenovia Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kinnate Biopharma (KNTE), Relay Therapeutics (RLAY) and Eyenovia (EYEN)